Apotex Launches Imatinib Tablets Generic Version of Novartis's Gleevec® with Patient Savings Card Program

Saturday, August 6, 2016 Drug News J E 4

WESTON, FL, Aug. 5, 2016 /PRNewswire/ - Apotex Corp. announced today that it has launched Imatinib Mesylate Tablets the generic equivalent of Gleevec® by Novartis.

"We are very excited to make a more affordable version of this important cancer medication available to the US market.  It demonstrates our continued dedication to provide high quality, cost saving generic products to the US health care system," said Jeff Watson, President, Global Generics, Apotex Inc.

To increase availability to patients, Apotex has also developed an Imatinib Instant Savings Card.  Apotex will announce more information on this exciting program through the website later this month.

Apotex's Imatinib Mesylate Tablets are now available in 100mg and 400mg strengths.  According to IMS Health, Gleevec® had approximately $2.4 billion in sales in the 12 months ending in May 2016.

Launching Imatinib Mesylate Tablets with the Imatinib Instant Savings Card is just another example of how Apotex is everywhere.  Making a difference.  One life at a time.

About ApotexApotex Inc. is the 7th largest generic pharmaceutical company globally (according to IMS Health) with over 10,000 employees and estimated sales of approximately $2 billion. The company's US headquarters is based in Weston, Florida. With its worldwide manufacturing sites, Apotex can produce up to 24 billion dosages per year. It produces 300 medicines in 4,000 dosages and formats that are exported to 120 countries. It has 300 products under development and will spend $2 billion over the next 10 years on research and development.

SOURCE Apotex Inc.



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Study Examines Big Data Presence, Utilization acro...
Advisory - Pharmascience Inc. voluntarily recalls ...